We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





Solutions Designed for Labs to Reduce Costs and Improve Productivity Showcased at the AACC Expo

By LabMedica International staff writers
Posted on 02 Aug 2013
Print article
Abbott (Abbott Park, IL, USA) features solutions to help labs prepare for the evolving healthcare environment. US healthcare providers are playing an increasingly important role in clinical labs to prevent medical errors, lower readmission rates, and improve patient care. Abbott showcased solutions designed to meet the needs of its lab customers while reducing costs and improving productivity at the American Association for Clinical Chemistry (AACC) annual meeting and clinical lab expo, July 28–August 1, 2013 in Houston (TX, USA).

Abbott also featured a variety of its solutions, including the first US Food and Drug Administration (FDA; Silver Spring, MD, USA)- approved genotyping test for hepatitis C (HCV), the RealTime HCV Genotype II test; the FDA-cleared FreeStyle Precision Pro Blood Glucose and β-Ketone Monitoring System; as well as the Accelerator a3600, a laboratory automation track system.

In addition, Abbott also showcased the company’s approach to customer-focused innovation through its program called "Factoring in the Human." On its recently launched Web site (please see Related Links below). Abbott shares the company’s focus on human factor principles and customer-centric approaches to influence product design. Laboratory professionals are encouraged to visit the website to learn more.

"Clinical laboratories are looking for the right solutions to successfully address the complexities and opportunities presented by the changing healthcare environment," said Greg Ahlberg, divisional vice president, US Commercial Operations, Diagnostics, Abbott. "Abbott has one of the broadest and most flexible portfolios available today to help labs drive efficiency and optimization, leading to improved patient care."

More than 30 scientific posters and/or oral presentations related to Abbott’s solutions will be presented during the AACC program. Seventeen posters cover cardiac markers and 13 focus on the performance of several clinical chemistry assays as well as on important areas, such as transplant, endocrine, metabolic, and congenitals.

Related Links:

Abbott
Abbott - Factoring the Human
US Food and Drug Administration


New
Gold Member
Veterinary Hematology Analyzer
Exigo H400
New
Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Celiac Disease Test
AESKULISA tTg-A New Generation
New
DVT/PE Test
VIDAS D-DIMER EXCLUSION II

Print article

Channels

Molecular Diagnostics

view channel
Image: Umbilical cord blood biomarkers may improve preterm infant care (Photo courtesy of Shutterstock)

Umbilical Cord Blood Test Could Identify Preterm Infants at Risk for Medical Complications

Advancements in medical technology and neonatology have significantly improved the care of prematurely born infants. However, these infants still face heightened risks for medical complications, such as... Read more

Immunology

view channel

3D Bioprinted Gastric Cancer Model Uses Patient-Derived Tissue Fragments to Predict Drug Response

Tumor heterogeneity presents a major obstacle in the development and treatment of cancer therapies, as patients' responses to the same drug can differ, and the timing of treatment significantly influences prognosis. Consequently, technologies that predict the effectiveness of anticancer treatments are essential in minimizing... Read more

Microbiology

view channel
Image: The Cytovale System isolates, images, and analyzes cells (Photo courtesy of Cytovale)

Rapid Sepsis Diagnostic Test Demonstrates Improved Patient Care and Cost Savings in Hospital Application

Sepsis is the leading cause of death and the most expensive condition treated in U.S. hospitals. The risk of death from sepsis increases by up to 8% for each hour that treatment is delayed, making early... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.